Ubs Group Ag Surface Oncology, Inc. Transaction History

Ubs Group Ag

  • $452 Billion
  • Q3 2024

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 11, 2023
SELL
$0.57 - $0.88 $5,090 - $7,858
-8,930 Reduced 56.5%
6,875 $5,000
Q1 2023

May 12, 2023
BUY
$0.61 - $1.03 $4,570 - $7,716
7,492 Added 90.12%
15,805 $11,000
Q4 2022

Feb 08, 2023
SELL
$0.62 - $1.21 $33,364 - $65,114
-53,814 Reduced 86.62%
8,313 $6,000
Q3 2022

Nov 10, 2022
SELL
$1.05 - $2.1 $124,482 - $248,965
-118,555 Reduced 65.62%
62,127 $65,000
Q2 2022

Aug 10, 2022
BUY
$1.42 - $3.15 $142,349 - $315,774
100,246 Added 124.63%
180,682 $297,000
Q1 2022

May 16, 2022
SELL
$2.65 - $5.08 $8,890 - $17,043
-3,355 Reduced 4.0%
80,436 $236,000
Q4 2021

Feb 14, 2022
BUY
$4.73 - $7.9 $313,012 - $522,790
66,176 Added 375.68%
83,791 $400,000
Q3 2021

Nov 15, 2021
BUY
$5.16 - $7.98 $17,265 - $26,701
3,346 Added 23.45%
17,615 $134,000
Q2 2021

Aug 13, 2021
BUY
$6.45 - $9.09 $18,079 - $25,479
2,803 Added 24.45%
14,269 $106,000
Q1 2021

May 12, 2021
BUY
$7.25 - $13.82 $28,753 - $54,810
3,966 Added 52.88%
11,466 $90,000
Q4 2020

Feb 11, 2021
BUY
$6.87 - $10.48 $51,525 - $78,600
7,500 New
7,500 $69,000
Q4 2019

Feb 14, 2020
SELL
$1.17 - $2.33 $1,510 - $3,008
-1,291 Closed
0 $0
Q3 2019

Nov 14, 2019
BUY
$1.4 - $2.84 $1,807 - $3,666
1,291 New
1,291 $2,000
Q2 2019

Aug 14, 2019
SELL
$2.75 - $4.89 $6,792 - $12,078
-2,470 Closed
0 $0
Q1 2019

May 14, 2019
BUY
$4.11 - $5.88 $1,754 - $2,510
427 Added 20.9%
2,470 $12,000
Q4 2018

Feb 14, 2019
SELL
$3.65 - $10.69 $23,184 - $67,902
-6,352 Reduced 75.66%
2,043 $9,000
Q3 2018

Nov 14, 2018
BUY
$8.92 - $17.83 $61,663 - $123,258
6,913 Added 466.46%
8,395 $92,000
Q2 2018

Aug 14, 2018
BUY
$12.83 - $17.41 $19,014 - $25,801
1,482 New
1,482 $24,000

Others Institutions Holding SURF

# of Institutions
2
Shares Held
315K
Call Options Held
0
Put Options Held
0
View Full List

About Surface Oncology, Inc.

SURF Quotes by TradingView
  • Ticker SURF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,034,000
  • Description
  • Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibo...
More about SURF
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email